U.S. Food and Drug Administration

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

9 Stories Indexed

Last Updated: Just Now

Verified Entity Intelligence

Big Tech, Cloud & Semiconductors 11 Nov 2026, 08:00 AM IST

FDA Flags Rare Vision Risk in GLP-1 Drugs as Use Surges

The U.S. Food and Drug Administration has warned that GLP-1 drugs, a fast-growing class of medicines used for diabetes and weight loss, may be linked to a rare eye condition that can cause sudden vision loss. The agency said the risk appears small and the evidence remains mixed, but it wants patients and clinicians to be aware as use of the drugs continues to expand globally.

By RDU Global Wire4 min read

Big Tech, Cloud & Semiconductors02 Nov 2026, 02:00 PM IST

FDA Moves to Withdraw Tavneos Approval, Exposing a Harder Question: What Happens to Patients Now?

The U.S. Food and Drug Administration is seeking to pull its approval of Tavneos after concluding the drug was cleared on the basis of manipulated study data, a rare and consequential move that could reverberate across drug regulation. The case highlights the tension between policing scientific integrity and preserving patient access to a treatment already on the market.

6 min readRead →

Global Markets & Equities15 Oct 2026, 11:54 PM IST

FDA Signals Stricter, More Predictable Rare Disease Drug Review Framework

The U.S. Food and Drug Administration’s new leadership is moving to reshape how rare disease therapies are evaluated, with an emphasis on consistency, predictability and a more structured approval pathway. The initiative could materially affect drug developers, investors and patients by narrowing the discretion that has long defined this corner of the regulatory process.

5 min readRead →

Global Markets & Equities15 Oct 2026, 02:39 PM IST

FDA Moves to Tighten Rare-Disease Drug Reviews as New Leadership Seeks Consistency

The U.S. Food and Drug Administration is advancing a new rare-disease framework that could reshape how experimental treatments are designed, reviewed and approved. The initiative signals a shift toward greater consistency and broader evidentiary standards, a move that may raise the bar for developers while potentially improving regulatory predictability.

6 min readRead →

Global Markets & Equities06 Oct 2026, 04:52 AM IST

FDA Says More Than 122,000 Cases of Gatorade Recalled Over Undeclared Food Dyes

The U.S. Food and Drug Administration says more than 122,000 cases of Gatorade have been recalled after undeclared food dyes were found in certain products, raising labeling and compliance concerns for one of the world’s best-known beverage brands. The recall spans 37 states and underscores how even a packaging or formulation disclosure lapse can trigger a broad consumer safety response and reputational risk for a major consumer staples company.

5 min readRead →

Global Markets & Equities06 Oct 2026, 04:30 AM IST

FDA Says More Than 122,000 Cases of Gatorade Recalled Over Undeclared Food Dyes

PepsiCo has recalled more than 122,000 cases of Gatorade after U.S. regulators said certain products contained undeclared food dyes, a labeling issue that can trigger compliance scrutiny and consumer safety concerns. The recall spans more than 30 states and underscores the operational and reputational risks tied to ingredient disclosure in the packaged beverage sector.

5 min readRead →

Global Markets & Equities04 Oct 2026, 06:28 PM IST

F.D.A. Elevates Salad Dressing Recall to Highest Risk Level as Salmonella Probe Widens

The U.S. Food and Drug Administration has classified a recall of Salata Salad Kitchen’s jalapeño avocado dressing as a Class I event, its most serious designation, after concerns that the product may be contaminated with Salmonella. The escalation raises the stakes for food safety regulators and underscores how a single condiment recall can ripple through consumer confidence, restaurant supply chains, and packaged-food equities.

5 min readRead →

Clean Energy & Climate Transition04 Oct 2026, 03:05 AM IST

At Seattle’s Pacific Science Center, the Dinosaurs Are a Test of Climate-Smart Reinvention

The Pacific Science Center’s dinosaur exhibit has become more than a crowd-pleasing attraction: it is now a window into how cultural institutions are adapting to the clean-energy and climate-transition era. As museums confront rising operating costs, decarbonization pressures, and changing public expectations, even a prehistoric display can reveal the economics of modernization. The question is not only what happened to the dinosaurs, but what their fate says about the future of science education in a warming world.

6 min readRead →

Global Markets & EquitiesJust now (06:05 AM IST)

Nationwide Blood Pressure Drug Recall Raises Fresh Quality-Control Concerns

A blood pressure medication has been recalled nationwide after failing FDA dissolution testing, a quality defect that can affect how the drug is absorbed in the body. Regulators have classified the action as a Class II recall, indicating a situation in which exposure may cause temporary or medically reversible adverse health consequences, though the likelihood of serious harm is considered remote.

5 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside U.S. Food and Drug Administration:

Washington, D.C.(7)United States(4)Gatorade(2)Department of Health and Human Services(2)Washington, D.C.(1)Washington(1)